EcoR1 Capital’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

EcoR1 Capital’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-14,978	Closed	-$6.7M	–	61
2019 Q4	$6.7M	Sell	14,978 -20,357	-58%	-$7.22M	0.6%	31
2019 Q3	$10.9M	Sell	35,335 -2,533	-7%	-$823K	1.37%	19
2019 Q2	$12M	Sell	37,868 -15,320	-29%	-$5.3M	1.22%	19
2019 Q1	$22.3M	Hold	53,188	–	–	2.06%	17
2018 Q4	$16.2M	Buy	53,188 +18,538	+54%	+$5.99M	1.62%	19
2018 Q3	$12.5M	Hold	34,650	–	–	1.12%	25
2018 Q2	$12.7M	Buy	+34,650	New	+$12.3M	1.21%	22
2016 Q3	–	Sell	-473	Closed	-$281K	–	39
2016 Q2	$281K	Sell	473 -5,845	-93%	-$3.55M	0.11%	32
2016 Q1	$3.18M	Hold	6,318	–	–	1.11%	25
2015 Q4	$4.18M	Hold	6,318	–	–	1.31%	20
2015 Q3	$2.98M	Hold	6,318	–	–	1.36%	14
2015 Q2	$3.58M	Buy	+6,318	New	+$17.5M	1.19%	16

Other funds holding EIGR

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital's EIGR Position: Q1 2020 in Review

EcoR1 Capital sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2020, closing a stake of 14,978 shares — an estimated $6.7M sold.

EcoR1 Capital first reported a position in EIGR in Q2 2015 and held it in 12 quarters. The position peaked at $22.3M in Q1 2019. 93 funds tracked by Wall St. Rank hold EIGR as of Q1 2020.

EcoR1 Capital reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
EcoR1 Capital sold 14,978 Eiger BioPharmaceuticals, Inc. shares in Q1 2020, an estimated $6.7M.
EcoR1 Capital first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2015 and held it in 12 quarters.
EcoR1 Capital's Eiger BioPharmaceuticals, Inc. position peaked at $22.3M in Q1 2019.
93 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2020.

Based on EcoR1 Capital's 13F filing for Q1 2020, filed 15 May 2020.